Dermatology Clinical Trials

Researchers want to learn if L19IL2 and L19TNF, alone or together, work well to treat melanoma when given with pembrolizumab. The people in this study have melanoma that has metastasized (spread) or is inoperable (cannot be taken out with surgery). Their cancers keep growing even after having immune-boosting therapy.

Doctors routinely use intensity-modulated radiation therapy (IMRT) after surgery to treat squamous cell carcinoma (cancer) of the tongue. IMRT delivers radiation directly to cancer cells from different angles by changing the radiation beam into multiple smaller beams. By targeting the tumor more precisely, IMRT reduces radiation damage to healthy tissue.

Researchers want to see if removing only 1 lymph node with cancer prevents melanoma from coming back in that area. The people in this study have melanoma that spread to just 1 lymph node.

In this study, researchers want to see if the drug HER3-DXd works well against advanced melanoma. HER3-DXd is called an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to specific proteins on cancer cells. The linked drug enters these cells and kills them without harming other cells.

Researchers are comparing pembrolizumab given after surgery for head and neck cancer with the usual treatment. The usual therapy includes chemotherapy and radiation therapy. The people in this study have head and neck cancer that came back or is a new primary cancer.

Roginolisib works by blocking a protein called PI3K-delta. By blocking this protein, roginolisib may strengthen your immune system's ability to fight cancer cells. It is taken orally (by mouth).

Researchers want to see if ficerafusp alfa plus pembrolizumab is safe and works well against head and neck cancer. They will assess different doses of ficerafusp alfa to find the best one. The people in this study have head and neck squamous cell carcinoma. Their cancers have come back or metastasized (spread) after treatment.

If you take part in this study, you will be randomly assigned to get one of these treatments:

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Cetuximab binds to a protein called EGFR, which is found on some types of tumor cells. This drug may help keep tumor cells from growing. Pembrolizumab helps the body's immune system attack the tumor and may interfere with tumor growth and spread.